Hila Magen

Especialização: Hematologist
35 anos de experiência
Fala:
English, Hebrew
Consultas online: disponível
Local de trabalho: Israel, Ramat Gan, Centro Médico Sheba
Chefia a unidade de Mieloma Múltiplo e Amiloidose; mais de 100 publicações científicas; pesquisadora principal de programas de terapia CAR-T.
A Dra. Hila Magen é uma hemato-oncologista israelense líder no Sheba Medical Center. Ela chefia a Unidade de Mieloma Múltiplo e Amiloidose. A Dra. Magen é especializada no tratamento de distúrbios complexos de células plasmáticas e mieloma de alto risco. Ela é pesquisadora principal de programas inovadores de terapia CAR-T no local de atendimento. Seu trabalho traz imunoterapias avançadas para o cuidado clínico de rotina.
- Autora de mais de 100 publicações científicas e estudos fundamentais sobre mieloma.
- Completou fellowships no MD Anderson e na Universidade de Ciências Médicas do Arkansas.
- Realiza terapia com células CAR-T e transplantes de medula óssea.
- Trabalha no Sheba Medical Center, classificado em 7º lugar mundial em 2026 pela Newsweek.

Consulta online com Hila Magen

Confortável e fácil

100% seguro e confidencial

$650

Serviços do médico

Ver mais

Como estamos indo?

1 de 3

As informações sobre este médico estão completas e claras

Discordo totalmente

Concordo totalmente

Qualificações

Dr. Hila Magen directs the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is an expert in plasma cell disorders and advanced cellular therapies. The specialist is a principal investigator for point-of-care CAR-T cell programs.

Specialization in Plasma Cell Disorders

Dr. Magen treats relapsed and refractory multiple myeloma. She treats amyloidosis and various plasma cell malignancies using precision medicine. The specialist integrates new immunotherapies into routine clinical care for high-risk patients. Her approach involves creating targeted treatment plans to improve long-term survival.

Advanced Cellular Therapies and Procedures

The doctor applies CAR-T cell therapy for blood cancers. She offers patients early access to treatments through international clinical trials. Dr. Magen performs or oversees several critical hematologic procedures:

CAR T-cell therapy — a treatment that uses genetically modified immune cells to attack cancer
Bone marrow transplantation from related and unrelated donors
Haploidentical stem cell transplantation
Therapeutic apheresis and plasmapheresis — procedures that filter and clean a patient's blood
Diagnostic bone marrow biopsy and immunohistochemistry

Work Experience and Leadership

Head of the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center
Instructor at Tel Aviv University
Principal Investigator for point-of-care CAR-T cell research studies
Active reviewer for several international medical journals

Education and International Training

Fellowship in Multiple Myeloma – University of Arkansas for Medical Sciences (UAMS)
Fellowship in Lymphocytic Leukemia – MD Anderson Cancer Center, USA
MD Degree in General Medicine

Research and Academic Achievements

Dr. Magen has authored over 100 scientific publications in peer-reviewed journals. She has contributed to multiple landmark studies regarding myeloma treatment protocols. The doctor frequently presents her clinical findings at international hematology conferences. She focuses her research on developing next-generation cellular therapies for refractory diseases.